Dr. Kyle Schachtschneider, Vice President of R&D and Services for Sus Clinicals, Inc. will present exciting research from the Oncopig Cancer Model® at the Society of Interventional Oncology Annual Meeting later this month.

Entitled “The Oncopig hepatocellular carcinoma (HCC) model as a tool for locoregional therapeutic studies,” Dr. Schachtschneider will share this research on Sunday, January 28 during presentations beginning at 3:30pm.

HCC is an aggressive disease, often with a poor prognosis. Locoregional therapies (LRTs) are widely used for liver cancer treatment, and large animal models can support evaluation of new LRTs. The Oncopig Cancer Model is an ideal platform for such research, with induction of HCC on demand, yielding tumors virtually indistinguishable from their human counterparts, just two weeks post induction. As such, the Oncopig^TM provides an ideal bridge between early mouse-based research and expensive human clinicals, helping cancer researchers move promising new therapies to the clinic faster.

Dr. Schachtschneider, a widely published expert on the pig as a biomedical research platform, and other Sus Clinicals representatives will be at SIO and available for discussions with attendees who may be interested in learning more about Oncopig-based capabilities. Please contact us to learn more.